Furthermore, hepatic expression of membrane-bound AOC3 and serum levels of sAOC3 are increased in patients with NAFLD, and levels of sAOC3 correlate with fibrosis stage and are predictive of progression to NASH16. Here, AOC3 is linked to metabolic dysfunction-associated steatotic liver disease.